Clinical Trials at Stanford University
As of September 2026, 127 paid clinical trials are recruiting at Stanford University, located at 780 WELCH RD, SUITE 106, PALO ALTO, CA 94304-1516, phone (650) 725-4738 in Palo Alto, California. Active studies at this site cover conditions such as Breast Cancer, Heart Failure and Chronic Lymphocytic Leukemia. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Palo Alto
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
Intervention on Mathematical Problem-Solving Skills
RB-PDT for Fusarium Keratitis: The LUMIERE Study
UPRIGHT-PRO: Prospective Development Study of Upright Proton Therapy
131 clinical trials at Stanford University
·Clear filters·BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury
US National OCS Heart Perfusion (OHP) Registry
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
SPEARHEAD-3 Pediatric Study
A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
Melodi Matrix™ in Breast Reconstruction
TVMR With the INNOVALVE System Trial - Early Feasibility Study
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Study With Phage for CF Subjects With Pseudomonas Lung Infection
Study of Intrathecal ELP-02 for Charcot-Marie-Tooth Disease Type 4J (CMT4J)
Inappropriate Sinus Tachycardia Registry
A Study of CTD402 in T-ALL/LBL Patients
AERA Pediatrics Registry
ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Prospective Multi-Center Trial for FemBloc Permanent Birth Control
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
Investigation to Evaluate the Safety and Effectiveness of Cochlear Implantation in Children and Adults With Unilateral Hearing Loss/Single-sided Deafness
A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
Empowering Monterey Bay Residents for Activated, Collaborative, and Equitable Care
Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical Trial
Common conditions studied in Palo Alto
- Cancer (9 active studies)
- Breast Cancer (8 active studies)
- Heart Failure (8 active studies)
- Chronic Lymphocytic Leukemia (7 active studies)
- Epilepsy (7 active studies)
- Acute Myeloid Leukemia (6 active studies)
Leading research sponsors in Palo Alto
- Stanford University
- VA Office of Research and Development
- National Cancer Institute (NCI)
- Children's Oncology Group
- NRG Oncology
Frequently asked questions
How many paid clinical trials are currently recruiting in Palo Alto?
There are approximately 655 recruiting clinical trials in Palo Alto, California listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Palo Alto pay participants?
Most recruiting trials in Palo Alto compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Palo Alto?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Palo Alto?
The most common conditions under active study in Palo Alto include Cancer (9), Breast Cancer (8), Heart Failure (8), Chronic Lymphocytic Leukemia (7), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Palo Alto?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Palo Alto on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Palo Alto?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Palo Alto?
Recruiting research sites in Palo Alto include Stanford University, Stanford Cancer Institute Palo Alto, Stanford University Medical Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Palo Alto right now?
The largest active categories in Palo Alto are Cancer & tumors (192), Neurology & pain (41), Cardiovascular (35). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Stanford University?
Stanford University is located at 780 WELCH RD, SUITE 106, PALO ALTO, CA 94304-1516. Use the Google Maps link in the intro above to get directions.
How do I contact Stanford University?
You can reach Stanford University by phone at (650) 725-4738. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.